Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 416 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Surfactant Deficiency Syndrome Neonatal Clear all
Completed Phase 2 Interventional Results available

Add-on Reparixin in Adult Patients With ARDS

NCT05496868
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Adult
Interventions
Reparixin 600mg, Matching Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 7, 2026, 7:00 AM EDT
Terminated No phase listed Observational

Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care

NCT00887731
View directory record Official record
Conditions
Respiratory Distress Syndrome, Hyperoxia, Prematurity
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 3 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 7, 2026, 7:00 AM EDT
No Longer Available No phase listed Expanded access

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

NCT04366830
View directory record Official record
Conditions
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Interventions
Remestemcel-L
Drug
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections

NCT04395911
View directory record Official record
Conditions
AKI, ARDS, COVID
Interventions
SCD
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Lexington, Kentucky • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 7, 2026, 7:00 AM EDT
Terminated Not applicable Interventional

The Effects of Different Ventilator Strategies on Inflammation and Injury in Normal Lungs

NCT01003730
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Ventilator settings
Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

NCT01597635
View directory record Official record
Conditions
Lung Injury, Acute
Interventions
Dose 1 GSK2586881, Dose 2 GSK2586881, Dose 3 GSK2586881, Dose 4 GSK2586881, Placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sacramento, California • Chicago, Illinois • Springfield, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Not applicable Interventional Results available

Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function

NCT04295564
View directory record Official record
Conditions
Neonatal, Premature Birth, Respiratory Distress Syndrome
Interventions
Additional 2 weeks of CPAP
Other
Lead sponsor
Cynthia McEvoy
Other
Eligibility
1 Day to 12 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 7, 2026, 7:00 AM EDT
Completed No phase listed Observational

Amphetamine Induced Adult Respiratory Distress Syndrome

NCT05611385
View directory record Official record
Conditions
Burns, Acute Lung Injury, Acute Respiratory Distress Syndrome, Methamphetamine Abuse
Interventions
Difference in development of Acute Lung Injury in Amphetamine positive and negative patients
Other
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 7, 2026, 7:00 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

hCT-MSCs for COVID19 ARDS

NCT04399889
View directory record Official record
Conditions
COVID, Corona Virus Infection, COVID19
Interventions
Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Not applicable Interventional

Work of Breathing During Non-invasive Ventilation in Premature Neonates

NCT02788110
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia
Interventions
Noninvasive neurally adjusted ventilatory assist (NIV NAVA), Nasal intermittent positive pressure ventilation (NIPPV)
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 12 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 7, 2026, 7:00 AM EDT
Terminated Not applicable Interventional

Neotech RAM Cannula Versus Conventional Binasal Prong Continuous Positive Airway Pressure (CPAP) to Treat Respiratory Distress in Low Birth Weight Neonates

NCT02168257
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Continuous Positive Airway Pressure, Low Birth Weight Infants
Interventions
RAM Cannula, Binasal Prong CPAP
Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Not applicable Interventional Results available

Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome

NCT02582957
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Sigh breaths
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 7, 2026, 7:00 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities

NCT03996317
View directory record Official record
Conditions
Perinatal Death, Respiratory Distress Syndrome, Newborn, Hypoxic-Ischemic Encephalopathy, Neonatal Seizure, Meconium Aspiration Syndrome, Intracranial Hemorrhages, Neonatal Hypotension
Interventions
Room air
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 7, 2026, 7:00 AM EDT
Not listed No phase listed Observational

Effect of Steroid Administration on Maternal Blood Levels of hLPCAT1 mRNA

NCT03562182
View directory record Official record
Conditions
Fetal Lung Maturity, Respiratory Distress Syndrome in Premature Infant
Interventions
blood draw
Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
80 participants
Timeline
2018 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

NCT00624650
View directory record Official record
Conditions
Acute Lung Injury
Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
Drug · Other · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Clackamas, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

NCT02452476
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
CHF5633, Poractant alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

NCT00036062
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury
Interventions
Sivelestat
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 7, 2026, 7:00 AM EDT
Withdrawn Phase 2 Interventional

Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation

NCT00793013
View directory record Official record
Conditions
Acute Lung Injury, Adult Respiratory Distress Syndrome, Kidney Injury
Interventions
Volume-Cycled Assist-Control (AC) mode, Airway Pressure Release Ventilation (APRV) mode
Device
Lead sponsor
University of Tennessee, Chattanooga
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 7, 2026, 7:00 AM EDT
Completed No phase listed Observational

Severe ARDS: Generating Evidence

NCT03021824
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Respiratory Failure With Hypoxia, Acute Respiratory Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 7, 2026, 7:00 AM EDT
Not yet recruiting No phase listed Observational

Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin. Group 1

NCT07249762
View directory record Official record
Conditions
Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions
Observational Cohort (No Intervention)
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 7, 2026, 7:00 AM EDT
No Longer Available No phase listed Expanded access

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

NCT04355494
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 7, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

NCT04389671
View directory record Official record
Conditions
COVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
Lucinactant
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • Augusta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 7, 2026, 7:00 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

NCT04565665
View directory record Official record
Conditions
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Mesenchymal Stem Cell
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 7, 2026, 7:00 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 7, 2026, 7:00 AM EDT